CAR-T Cells for the Treatment of Central Nervous System Tumours: Known and Emerging Neurotoxicities
The advent of chimeric antigen receptor (CAR)-T cells has recently changed the prognosis of relapsing/refractory diffuse large B-cell lymphomas, showing response rates as high as 60 to 80%. Common toxicities reported in the pivotal clinical trials include the cytokine release syndrome (CRS) and the...
Sparad:
| Huvudupphov: | , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
MDPI AG
2024-11-01
|
| Serie: | Brain Sciences |
| Ämnen: | |
| Länkar: | https://www.mdpi.com/2076-3425/14/12/1220 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|